The elongation of very long chain fatty acids: an overview
Fatty acid chain length is not fixed at synthesis. Cells extend existing fatty acids two carbons at a time using a family of endoplasmic reticulum-bound enzymes known as ELOVLs — short for elongation of very long chain fatty acids. The reaction proceeds through four enzymatic steps: condensation of the incoming acyl-CoA with malonyl-CoA (the rate-limiting step, performed by the ELOVL enzyme itself), followed by reduction, dehydration, and a second reduction, each catalysed by shared enzymes (3-ketoacyl-CoA reductase, 3-hydroxyacyl-CoA dehydratase, and trans-2-enoyl-CoA reductase respectively). The product is a fatty acyl-CoA two carbons longer than the substrate. Successive cycles stack these extensions to produce fatty acids far longer than the products of de novo lipogenesis — up to C36 in the retina.
Seven ELOVL paralogues exist in mammals (ELOVL1–7), each with a distinct and largely non-overlapping substrate preference determined by the length and degree of unsaturation of the acyl-CoA entering the condensation reaction. Their tissue expression also differs markedly, allowing different organs to build the specific very long chain fatty acid (VLCFA) compositions they require. Understanding each ELOVL in turn — its substrates, its products, and its physiological role — is the foundation for understanding how spirulina's fatty acid composition intersects with this pathway.
ELOVL1: saturated and monounsaturated ceramide elongation
ELOVL1 handles the elongation of saturated and monounsaturated fatty acids with chain lengths from C22 onwards, extending them to C26 and beyond. Its primary physiological role is in sphingolipid biosynthesis — specifically in producing the C24–C26 acyl chains that are transferred onto sphingosine backbones to form ceramides in the skin epidermis and other tissues.
The clinical importance of ELOVL1 became clear when heterozygous loss-of-function mutations were linked to a rare autosomal dominant neurocutaneous syndrome featuring ichthyosis (abnormal skin cornification) and spastic paraplegia. Homozygous loss-of-function in mice produces severe ichthyosis with a defective epidermal permeability barrier and neonatal death, reflecting the critical role of very long chain ceramides in forming the corneocyte lipid envelope — the lamellar lipid structure between cornified cells that provides the skin's water barrier. This barrier requires ceramides with acyl chains of C24–C26 length; ceramides with shorter chains produce a less effective barrier.
ELOVL2: DHA synthesis from EPA in the brain
ELOVL2 is the rate-limiting enzyme for DHA (docosahexaenoic acid, 22:6ω3) biosynthesis from EPA (eicosapentaenoic acid, 20:5ω3) via the Sprecher pathway. The sequence proceeds: EPA (20:5ω3) is elongated by ELOVL2 to C22:5ω3, then elongated again to C24:5ω3, followed by desaturation by Δ6-desaturase (FADS2) to C24:6ω3, and finally chain-shortened by peroxisomal β-oxidation to DHA (22:6ω3). This indirect route — elongate, elongate, desaturate, shorten — is the primary endogenous pathway for DHA production in humans and explains why EPA supplementation partially but incompletely raises DHA tissue levels.
ELOVL2 expression is highest in liver and testis, with lower but significant expression in brain and retina. The enzyme is subject to epigenetic regulation — its promoter CpG island is differentially methylated across tissues and during ageing, with ELOVL2 methylation being among the most precisely age-correlated CpG sites in the human genome (it is one of the clock CpGs in several epigenetic age models including Hannum's clock). Decreased ELOVL2 expression with ageing contributes to the well-documented decline in DHA biosynthetic capacity in older adults, making dietary DHA intake increasingly important with age.
ELOVL2 also elongates DPA (docosapentaenoic acid, 22:5ω6), the ω6 counterpart of DHA, in competition with the ω3 pathway. When the ω6/ω3 ratio in tissues is high — as it tends to be in Western diets — ELOVL2 is partly occupied with ω6 elongation, reducing the flux toward DHA. This competition is one of the mechanistic explanations for why high dietary linoleic acid (18:2ω6) reduces DHA status.
ELOVL3: wax ester synthesis and hair follicle skin barrier
ELOVL3 is primarily expressed in sebaceous glands and brown adipose tissue, with a specialised role in wax ester synthesis. Wax esters in sebum — fatty alcohols esterified to fatty acids — depend on ELOVL3 for the very long chain fatty acid component. ELOVL3-knockout mice display abnormal sebaceous glands, altered sebum composition, and defective hair follicle-associated skin barrier integrity. The enzyme acts on C20–C24 saturated and monounsaturated substrates. Its brown adipose expression correlates with thermogenesis — cold exposure upregulates ELOVL3 in mice — though the specific role of wax esters in adipose thermogenesis remains under investigation.
ELOVL4: retinal C28–C32 very long chain PUFAs and Stargardt disease
ELOVL4 is remarkable for producing the longest fatty acids in the mammalian body: polyunsaturated fatty acids with chain lengths from C28 to C36, found almost exclusively in the retina (particularly photoreceptor outer segments), testis (in spermatozoa plasma membranes), and skin. The retinal very long chain PUFAs — notably 32:6ω3 — constitute a unique lipid class whose function remains incompletely understood but appears related to the biophysical properties of photoreceptor disk membranes, supporting the extremely high DHA content (50% of total fatty acids) required for rhodopsin function and phototransduction.
The clinical relevance is stark. Dominant mutations in ELOVL4 cause Stargardt macular dystrophy — the most common inherited form of macular degeneration, producing progressive central vision loss beginning in adolescence or early adulthood due to photoreceptor and retinal pigment epithelium degeneration. The mutations cluster in the C-terminal ER retention signal of ELOVL4, causing the protein to accumulate in the trans-Golgi network and act as a dominant negative, reducing production of retinal VLCPUFAs. ELOVL4 is also required for the very long chain ceramides (C28–C32) in skin, and its mutation causes an autosomal recessive ichthyosis resembling the ELOVL1 phenotype.
ELOVL5: GLA to DGLA — the spirulina-relevant elongation step
ELOVL5 is the elongase most directly relevant to spirulina’s fatty acid content. Its primary substrates are C18 and C20 polyunsaturated fatty acids — specifically, it elongates gamma-linolenic acid (GLA, 18:3ω6) to dihomo-gamma-linolenic acid (DGLA, 20:3ω6), and elongates stearidonic acid (SDA, 18:4ω3) to eicosatetraenoic acid (ETA, 20:4ω3). Both are important metabolic junctions. The GLA→DGLA conversion by ELOVL5 is the step that gates the downstream production of DGLA-derived eicosanoids.
DGLA sits at a critical branch point. It can be converted by COX-1 and COX-2 (cyclooxygenase enzymes) to 1-series prostaglandins — PGE1, PGI1, TXA1 — which are generally anti-inflammatory and vasodilatory, contrasting with the 2-series prostaglandins (PGE2, PGI2, TXA2) derived from arachidonic acid (AA, 20:4ω6), which are pro-inflammatory. DGLA can also be converted by 5-LOX to 15-HETrE (15-hydroxy-eicosatrienoic acid), which inhibits 5-lipoxygenase activity and thereby reduces leukotriene production from AA — another anti-inflammatory effect. Alternatively, DGLA can be desaturated by Δ5-desaturase (FADS1) to AA, which is the pro-inflammatory route.
The balance between these fates — DGLA → anti-inflammatory 1-series eicosanoids, versus DGLA → AA → pro-inflammatory 2-series — is partly controlled by the relative activity of Δ5-desaturase (FADS1) and COX enzymes. When Δ5-desaturase activity is high (as in many metabolic disease states), DGLA is rapidly converted to AA. When it is lower, DGLA accumulates and more flows toward the anti-inflammatory 1-series pathway.
Spirulina’s notable GLA content — approximately 1.0–1.5 g per 100 g dry weight, constituting roughly 20–30% of total fatty acids in most commercial spirulina — provides substrate directly for ELOVL5. Dietary GLA bypasses the rate-limiting Δ6-desaturase step (the conversion of linoleic acid 18:2ω6 → GLA), which is often the bottleneck in ω6 PUFA elongation. By providing GLA preformed, spirulina can increase DGLA levels more efficiently than consuming linoleic acid alone, provided ELOVL5 activity is adequate. This is part of the mechanistic logic behind spirulina’s documented anti-inflammatory effects in clinical trials — including reductions in PGE2 and pro-inflammatory cytokines — though whether the GLA→DGLA→1-series pathway is the primary mechanism or one of several remains to be fully resolved.
ELOVL6: the C16 to C18 step and lipotoxicity sensing
ELOVL6 controls the elongation of palmitate (C16:0) to stearate (C18:0) and palmitoleate (C16:1ω7) to vaccenate (C18:1ω7). This seemingly minor step has outsized metabolic importance. The C16:0/C18:0 ratio determines the properties of cellular membranes and of the ceramides produced by ceramide synthases — C16:0-ceramide and C18:0-ceramide have different effects on mitochondrial function and apoptotic signalling. ELOVL6-knockout mice are paradoxically protected from diet-induced insulin resistance despite obesity, through an alteration in hepatic lipid composition that improves insulin receptor substrate signalling. ELOVL6 has been described as a “lipotoxicity sensor” because its substrate, palmitate, is the saturated fatty acid most strongly associated with lipotoxic injury in pancreatic beta cells and hepatocytes. Changing the palmitate/stearate ratio through ELOVL6 activity modulates the cellular response to lipid overload.
ELOVL7: prostate cancer overexpression
ELOVL7 has a narrower substrate range targeting C16–C20 saturated and monounsaturated substrates and is expressed most highly in prostate tissue. Its clinical relevance comes from studies showing that ELOVL7 is significantly overexpressed in prostate cancer, where it appears to support tumour growth by increasing the supply of very long chain saturated fatty acids for membrane synthesis and possibly for ligand production for androgen receptor activation. Knockdown of ELOVL7 in prostate cancer cell lines reduces tumour cell growth in vitro. Whether dietary interventions can modulate ELOVL7 expression in prostate tissue is not established.
The skin barrier ceramide connection
The connection between ELOVL elongases and skin barrier function operates through ceramide biosynthesis. The epidermal permeability barrier consists of lamellar bodies — lipid-rich organelles secreted by keratinocytes at the granular-cornified cell interface — that spread between corneocytes to form stacked bilayer lipid lamellae. These lamellae consist primarily of ceramides (approximately 50% by weight), cholesterol, and free fatty acids in a specific molar ratio. The ceramides require ultra-long acyl chains — predominantly C24–C26 — provided by ELOVL1 and ELOVL4, esterified onto sphingosine or phytosphingosine backbones by the ceramide synthases CerS1, CerS2, and CerS3 with different chain length preferences.
Deficiency in C24+ ceramides — whether due to ELOVL1 mutation, CerS2 mutation, or simply suboptimal fatty acid substrate availability — produces a leakier barrier with higher transepidermal water loss (TEWL), increased sensitivity to irritants, and lower threshold for atopic dermatitis-like inflammation. Providing adequate substrate for the ELOVL1 elongation steps (C22:0 → C24:0 → C26:0) is therefore relevant to maintaining ceramide chain length distribution and barrier function.
Several clinical trials have examined phycocyanin or spirulina supplementation in atopic dermatitis, with encouraging signals in some studies. The mechanism is typically attributed to phycocyanin’s antioxidant and anti-inflammatory properties — its inhibition of NF-κB and COX-2 reducing inflammatory cytokines in skin. A speculative but coherent additional mechanism involves the ELOVL5 substrate provision pathway: if spirulina’s GLA increases DGLA, and DGLA-derived 1-series prostaglandins reduce skin inflammation, this could create conditions in which ceramide synthesis enzymes in keratinocytes function more effectively, gradually improving barrier quality. Whether this chain of events actually contributes to the observed clinical improvements in atopic dermatitis is not established by any direct evidence — it is a hypothesis that would require ceramide profiling in skin biopsies before and after spirulina supplementation to test.
The brain ELOVL2/ELOVL4 axis and DHA homeostasis
The brain’s extraordinary lipid composition — with DHA constituting 40–50% of polyunsaturated fatty acids in grey matter and being concentrated particularly in synaptosomes and myelin — depends on the continuous supply and retention of DHA. Brain cells themselves express ELOVL2 (astrocytes and oligodendrocytes more than neurons) and ELOVL4 (retinal cells, neurons), and the collaboration between ELOVL2-mediated DHA synthesis and ELOVL4-mediated C28–C36 VLCPUFA synthesis constitutes the brain’s elongase axis for the most complex lipids in the nervous system.
Ageing-associated methylation of the ELOVL2 promoter — reducing its expression — is one of the most reproducible age-related epigenetic changes in human tissues and provides a mechanistic basis for the increased dietary DHA requirement in older adults. Whether this methylation is reversible by dietary or nutritional interventions, including antioxidant-rich foods like spirulina, is an open question. Oxidative stress promotes DNA methyltransferase activity at certain loci, and reducing oxidative burden chronically could theoretically slow the methylation-mediated silencing of ELOVL2, though this specific link has not been examined for spirulina.
How spirulina's GLA connects to this pathway
To summarise the connection clearly: spirulina contains preformed GLA (18:3ω6), which is a direct substrate for ELOVL5 to produce DGLA (20:3ω6). DGLA is the immediate precursor to 1-series prostaglandins via COX and to 15-HETrE via 5-LOX — both with anti-inflammatory properties — and the precursor to arachidonic acid via FADS1 Δ5-desaturase, which goes the other way.
The relationship between spirulina and the other ELOVL enzymes is more indirect. Spirulina does not contain the C22:0 or C24:0 substrates for ELOVL1-mediated ceramide elongation in meaningful amounts. It contains EPA in small quantities (less than 0.5% of total fatty acids in most commercial strains), providing minimal direct substrate for ELOVL2-mediated DHA synthesis; spirulina is not an EPA or DHA source in a practical sense. The connections to ELOVL3 (wax esters), ELOVL4 (retinal VLCPUFAs), ELOVL6 (C16/C18 balance), and ELOVL7 (prostate cancer) are even less direct — these operate through ELOVL pathways that spirulina does not meaningfully influence via substrate provision.
The more indirect ELOVL-relevant effects of spirulina involve phycocyanin’s anti-inflammatory and antioxidant actions modulating the cellular environment in which ELOVL enzymes operate. ER redox state, ceramide synthase activity, and the balance of fatty acid desaturase/elongase flux are all sensitive to oxidative stress and inflammatory signalling — pathways that phycocyanin demonstrably modulates. But attributing specific ELOVL-pathway effects to phycocyanin’s antioxidant action requires experimental evidence that does not yet exist in the literature.
Clinical and practical implications
The ELOVL pathway perspective adds mechanistic depth to spirulina’s GLA content — explaining not just “spirulina has anti-inflammatory fatty acids” but precisely which elongation step (ELOVL5), which downstream product (DGLA), and which eicosanoid pathway (1-series prostaglandins, 15-HETrE inhibition of leukotriene synthesis) are involved.
For practical decisions, this mechanism supports using spirulina as part of a strategy to shift ω6 eicosanoid balance toward the less inflammatory DGLA-derived mediators, particularly for people whose diet provides adequate linoleic acid (essentially everyone in developed countries) but who may have impaired Δ6-desaturase activity — a common finding in ageing, diabetes, and zinc or B6 deficiency. By bypassing the Δ6-desaturase step, spirulina’s GLA provides a more direct route to DGLA.
The connection to skin ceramide biology and atopic dermatitis via the ELOVL pathway remains speculative but coherent — and the published clinical signals in atopic dermatitis with spirulina supplementation are worth following up with appropriately mechanistic studies that measure ceramide profiles and barrier function endpoints rather than just symptom scores.